Selected article for: "analyze time and Coronavirus disease"

Author: Morgan, Camille E.; Rimland, Casey A.; Bell, Griffin J.; Kim, Min K.; Hedrick, Tanner; Marx, Ashley; Bramson, Brian; Swygard, Heidi; Napravnik, Sonia; Schmitz, John L.; Carson, Shannon S.; Fischer, William A.; Eron, Joseph J.; Gay, Cynthia L.; Parr, Jonathan B.
Title: Rapid analysis of local data to inform off-label tocilizumab use early in the COVID-19 pandemic
  • Cord-id: h2rh5bjl
  • Document date: 2021_9_9
  • ID: h2rh5bjl
    Snippet: The interleukin-6 receptor antagonist tocilizumab became widely used early in the coronavirus disease 2019 (COVID-19) pandemic based on small observational studies that suggested clinical benefit in COVID-19 patients with a hyperinflammatory state. To inform our local treatment algorithms in the absence of randomized clinical trial results, we performed a rapid analysis of the first 11 hospitalized COVID-19 patients treated with tocilizumab at our academic medical center. We report their early c
    Document: The interleukin-6 receptor antagonist tocilizumab became widely used early in the coronavirus disease 2019 (COVID-19) pandemic based on small observational studies that suggested clinical benefit in COVID-19 patients with a hyperinflammatory state. To inform our local treatment algorithms in the absence of randomized clinical trial results, we performed a rapid analysis of the first 11 hospitalized COVID-19 patients treated with tocilizumab at our academic medical center. We report their early clinical outcomes and describe the process by which we assembled a team of diverse trainees and stakeholders to extract, analyze, and disseminate data during a time of clinical uncertainty.

    Search related documents:
    Co phrase search for related documents
    • academic medical system and admission time: 1
    • admission time and local practice: 1
    • admission time and local treatment: 1, 2
    • admission time and low baseline: 1, 2